Product Description
IGM-2644 is a T cell engaging IgM antibody targeting CD38 for the treatment of patients with multiple myeloma. IGM plans to file an IND application in 2022 with the U.S. Food and Drug Administration (FDA) for IGM-2644 to begin clinical testing in multiple myeloma. (Sourced from: https://igmbio.com/pipeline/igm-2644/)
Mechanisms of Action: CD38 Inhibitor,CD3 Inhibitor
Novel Mechanism: No
Modality: Bispecific Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: IGM Biosciences
Company Location: MOUNTAIN VIEW CA 94043
Company CEO: Fred Schwarzer
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Multiple Myeloma
Phase 0: Autoimmune Disease Unspecified|Multiple Myeloma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
IGM-2644-001 | P1 |
Terminated |
Multiple Myeloma |
2024-02-16 |